Luo Mi, Rehman Abdul, Haque Soha, Izhar Saba, Perveen Fauzia, Haris Muhammad, Abdel-Maksoud Mostafa A, Saleh Ibrahim A, Zomot Naser, Malik Abdul, Alamri Abdulaziz, Kodous Ahmad S, Aufy Mohammed, Zaky Mohamed Y, Zaeem Muhammad, Hameed Yasir, Li Junwei
Department of Infectious Disease, The School of Public Health of Nanjing Medical University, The Second Hospital of Nanjing Nanjing 210037, Jiangsu, China.
District Blood Bank Sialkot, AIMTH Sialkot, Pakistan.
Am J Transl Res. 2024 Mar 15;16(3):940-954. doi: 10.62347/QNNE5428. eCollection 2024.
To elucidate the expression levels and prognostic value of the Lipoyltransferase 2 (LIPT2) gene in a pan-cancer view.
Our study comprehensively investigated the role of LIPT2 in pan-cancer, combining bioinformatics analyses with experimental validations.
Analysis of LIPT2 mRNA expression across various cancers revealed a significant up-regulation in 18 tumor types and down-regulation in 8 types, indicating its diverse involvement. Prognostic assessment demonstrated a correlation between elevated LIPT2 expression and poorer outcomes in Overall Survival (OS) and Disease-Free Survival (DFS), particularly in Glioblastoma Multiforme (GBM), Liver Hepatocellular Carcinoma (LIHC), and Pheochromocytoma and Paraganglioma (PCPG). Protein expression analysis in GBM, LIHC, and PCPG affirmed a consistent increase in LIPT2 levels compared to normal tissues. Examining the methylation status in GBM, LIHC, and PCPG, we found reduced promoter methylation levels in tumor samples, suggesting a potential influence on LIPT2 function. Genetic mutation analysis using cBioPortal indicated a low mutation frequency (< 2%) in LIPT2 across GBM, LIHC, and PCPG. Immune correlation analysis unveiled a positive association between LIPT2 expression and infiltration levels of immune cells in GBM, LIHC, and PCPG. Single-cell analysis illustrated LIPT2's positive correlation with functional states, including angiogenesis and inflammation. Enrichment analysis identified LIPT2-associated processes and pathways, providing insights into its potential molecular mechanisms. Drug sensitivity analysis demonstrated that elevated LIPT2 expression conferred resistance to multiple compounds, while lower expression increased sensitivity. Finally, RT-qPCR validation in HCC cell lines confirmed the heightened expression of LIPT2 compared to a control cell line, reinforcing the bioinformatics findings.
Overall, our study highlights LIPT2 as a versatile player in cancer, influencing diverse aspects from molecular processes to clinical outcomes across different cancer types.
从泛癌角度阐明硫辛酰转移酶2(LIPT2)基因的表达水平及预后价值。
我们的研究结合生物信息学分析与实验验证,全面探究了LIPT2在泛癌中的作用。
对多种癌症中LIPT2 mRNA表达的分析显示,18种肿瘤类型中显著上调,8种类型中下调,表明其参与情况多样。预后评估表明,LIPT2表达升高与总生存期(OS)和无病生存期(DFS)较差相关,尤其是在多形性胶质母细胞瘤(GBM)、肝细胞肝癌(LIHC)以及嗜铬细胞瘤和副神经节瘤(PCPG)中。GBM、LIHC和PCPG中的蛋白质表达分析证实,与正常组织相比,LIPT2水平持续升高。检测GBM、LIHC和PCPG中的甲基化状态,我们发现肿瘤样本中启动子甲基化水平降低,提示对LIPT2功能可能有影响。使用cBioPortal进行的基因突变分析表明,GBM、LIHC和PCPG中LIPT2的突变频率较低(<2%)。免疫相关性分析揭示了GBM、LIHC和PCPG中LIPT2表达与免疫细胞浸润水平呈正相关。单细胞分析表明LIPT2与包括血管生成和炎症在内的功能状态呈正相关。富集分析确定了与LIPT2相关的过程和途径,为其潜在分子机制提供了见解。药物敏感性分析表明,LIPT2表达升高赋予对多种化合物的抗性,而较低表达则增加敏感性。最后,肝癌细胞系中的RT-qPCR验证证实,与对照细胞系相比,LIPT2表达升高,强化了生物信息学研究结果。
总体而言,我们的研究突出了LIPT2作为癌症中一个多功能的因子,影响从分子过程到不同癌症类型临床结局的多个方面。